Document Type


Publication Date



Neurotrophic keratopathy (NK) is a rare disease secondary to the damage or degradation of corneal nerves, which results in a compromised integrity of the tear film, corneal epithelium, and stroma. Oxervate, a topical recombinant human nerve growth factor approved by the FDA in August 2018, has shown promising results in healing neurotrophic corneal ulcers and preventing recurrence of this disease. Our preliminary display of results on four patients treated with oxervate provides further insight on the pathophysiology of NK and the mechanism of action of oxervate.

Academic Level

medical student

Available for download on Monday, July 13, 2026